Twin sisters living with heart failure are calling for an end to what they say is a postcode lottery when it comes to ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Beta blockers are go-to meds for many people who've survived a heart attack, but might not be needed for patients whose ...

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...

Researchers have found a potential method to slow heart failure progression. They fed mice a diet high in soybean protein, which influenced gut bacteria and supported heart health. Analysis showed ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure ...